Subgroup,Proportion,Decline Rate,Description,Total Costs,Total QALYs,Life Years,Time to ESKD,Incremental Costs,Incremental QALYs,ICER
Super-responders (20%),20%,0.2,"Excellent biodistribution, early treatment",1292813.7876248457,21.767240583497315,50.079233880171365,100.0,-70038.32037640642,8.198152850296218,-8543.18303834452
Good responders (50%),50%,0.52,"Good biodistribution, typical response",1287979.6742311795,21.291865396431554,48.750099783621074,100.0,-74872.43377007265,7.722777663230456,-9695.01350874749
Poor responders (25%),25%,1.04,Suboptimal biodistribution or late treatment,1283436.843090453,17.685859215307907,39.624071217240676,100.0,-79415.26491079922,4.1167714821068095,-19290.666303915772
Non-responders (5%),5%,2.48,No treatment benefit,1569706.9115393967,13.569087733201098,31.301737823276916,30.0,206854.80353814457,0.0,inf
Population Average (weighted),100%,Mixed,Weighted average across all subgroups,1301897.150990142,20.099300005402274,45.862001363318825,,-60954.95701111015,6.530212272201176,-9334.299479144453
